The effects of CGRP pathway monoclonal antibody treatment on inner ear function in patients with migraine: a prospective study

The effects of CGRP pathway monoclonal antibody treatment on inner ear function in patients with migraine: a prospective study - The effects of CGRP pathway monoclonal antibody treatment on inner ear function in patients with migraine: a prospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048360

Enrollment

Registered

2022-07-13

Start date

2022-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The migraine patients who needed inner ear function tests Vestibular migraine patients are eligible

Exclusion criteria

Exclusion criteria: Treatment duration is less than 3 months The patients with migraine with brainstem aura

Design outcomes

Primary

Measure	Time frame
The improvement of inner ear function after 6-months treatment with CGRP pathway monoclonal antibody	—

Countries

Japan

Contacts

Public ContactDaisuke DANNO

Tominaga Hospital Headache center, Department of neurology

daisuke_danno@yahoo.co.jp06-6568-1601

Outcome results